Atlas Trials

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Clinical trial NCT07392346 · RECRUITING

Trial details

NCT number
NCT07392346
Sponsor
Dai, Guanghai
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric Cancer Adenocarcinoma Metastatic
Start date
2025-12-01
Primary completion
2027-11-30
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.